Immunotherapy of breast cancer by single delivery with rAAV2-mediated interleukin-15 expression

International Journal of Oncology

Volumn 36, Issue 2, 2010, Pages 365-370

  Yu, Yung Luen ^a,b   Wei, Chyou Wei ^c   Chen, Y I Lin ^d   Chen, Mark Hung Chih ^c   Yiang, Giou Teng ^e  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b ASIA UNIVERSITY   (Taiwan)

^c HUNGKUANG UNIVERSITY   (Taiwan)

^d NATIONAL ILAN UNIVERSITY   (Taiwan)

^e TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Breast cancer; hIL15; Immunotherapy; LAK cells; rAAV2

Indexed keywords

ADENOVIRUS VECTOR; RECOMBINANT INTERLEUKIN 15;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; IN SITU NICK-END LABELING; INTERLEUKIN-15; KILLER CELLS, LYMPHOKINE-ACTIVATED; MICE; MICE, INBRED BALB C;

EID: 75449109194     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000508     Document Type: Article

References (28)

1. Ponnazhagan S, Curiel DT, Shaw DR, Alvarez RD and Siegal GP: Adeno-associated virus for cancer gene therapy. Cancer Res 61: 6313-6321, 2001.
2. Xiao X, Li J and Samulski RJ: Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 70: 8098-8108, 1996.
3. Ma HI, Guo P, Li J, et al: Suppression of intracranial human glioma growth after intramuscular administration of an adenoassociated viral vector expressing angiostatin. Cancer Res 62: 756-763, 2002.
4. Zhang JF, Hu C, Geng Y, Blatt LM and Taylor MW: Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression. Cancer Gene Ther 3: 31-38, 1996.
5. Liu DW, Tsao YP, Kung JT, et al: Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 74: 2888-2894, 2000.
6. Hildinger M and Auricchio A: Advances in AAV-mediated gene transfer for the treatment of inherited disorders. Eur J Hum Genet 12: 263-271, 2004.
7. Emborg ME, Carbon M, Holden JE, et al: Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab 27: 501-509, 2007.
8. Kaplitt MG, Feigin A, Tang C, et al: Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369: 2097-2105, 2007.
9. Rao VS, Dyer CE, Jameel JK, Drew PJ and Greenman J: Potential prognostic and therapeutic roles for cytokines in breast cancer (Review). Oncol Rep 15: 179-185, 2006.
10. Dougan M and Dranoff G: Immune therapy for cancer. Annu Rev Immunol 27: 83-117, 2009.
11. Carson WE, Giri JG, Lindemann MJ, et al: Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 180: 1395-1403, 1994.
12. Munger W, DeJoy SQ, Jeyaseelan R Sr, et al: Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol 165: 289-293, 1995.
13. + hematopoietic progenitor cells. Blood 87: 2632-2640, 1996.
14. Armitage RJ, Macduff BM, Eisenman J, Paxton R and Grabstein KH: IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol 154: 483-490, 1995.
15. Gamero AM, Ussery D, Reintgen DS, Puleo CA and Djeu JY: Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. Cancer Res 55: 4988-4994, 1995.
16. Grimm EA, Robb RJ, Roth JA, et al: Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med 158: 1356-1361, 1983.
17. Sparano JA, Fisher RI, Weiss GR, et al: Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors. J Immunother Emphasis Tumor Immunol 16: 216-223, 1994.
18. Lieberman J: The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol 3: 361-370, 2003.
19. Ferrini S, Azzarone B and Jasmin C: Is IL-15 a suitable candidate for cancer gene therapy? Gene Ther 3: 656-657, 1996.
20. Kimura K, Nishimura H, Hirose K, Matsuguchi T, Nimura Y and Yoshikai Y: Immunogene therapy of murine fibrosarcoma using IL-15 gene with high translation efficiency. Eur J Immunol 29: 1532-1542, 1999.
21. Yiang GT, Harn HJ, Yu YL, et al: Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice. J Biomed Sci 16: 47, 2009.
22. Zolotukhin S, Byrne BJ, Mason E, et al: Recombinant adenoassociated virus purification using novel methods improves infectious titer and yield. Gene Ther 6: 973-985, 1999.
23. Auricchio A, Hildinger M, O'Connor E, Gao GP and Wilson JM: Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther 12: 71-76, 2001.
24. Gao G, Qu G, Burnham MS, et al: Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum Gene Ther 11: 2079-2091, 2000.
25. Wang Z, Ma HI, Li J, Sun L, Zhang J and Xiao X: Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 10: 2105-2111, 2003.
26. Kutzler MA, Robinson TM, Chattergoon MA, et al: Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol 175: 112-123, 2005.
27. Chirmule N, Propert K, Magosin S, Qian Y, Qian R and Wilson J: Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6: 1574-1583, 1999.
28. Fisher KJ, Jooss K, Alston J, et al: Recombinant adenoassociated virus for muscle directed gene therapy. Nat Med 3: 306-312, 1997.